Natco Pharma Board Meeting on Nov 13 to Consider Unaudited Results, Dividend

Natco Pharma Ltd has announced that its Board of Directors will convene on November 13, 2026. The primary agenda items include the consideration and approval of the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. Additionally, the Board will deliberate on the potential declaration of a second interim dividend for the financial year ending 2026-27. The company also confirmed the closure and subsequent reopening of the trading window for its securities, in compliance with SEBI regulations.